Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

(2013) L. Bonanno et al.   ANNALS OF ONCOLOGY

Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2013) Gerold Bepler et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetics and biomarkers in personalisation of lung cancer treatment

(2013) Rafael Rosell et al.   LANCET

RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1

(2012) S. Nakada et al.   CANCER RESEARCH

BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair

(2012) Samuel F. Bunting et al.   MOLECULAR CELL

The DNA damage response and cancer therapy

(2012) Christopher J. Lord et al.   NATURE

mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric Cancer

(2011) Jia Wei et al.   JNCI-Journal of the National Cancer Institute

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer

(2010) T. G. Oliver et al.   GENES & DEVELOPMENT

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

(2009) Rafael Rosell et al.   PLoS One

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

(2008) Lifeng Wang et al.   BMC CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients

(2008) Ioannis Boukovinas et al.   PLoS One